메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류
인문학
인문학 일반 역사학 철학 종교학 어문학 기타 인문학
사회과학
사회과학 일반 경영학 관광학 교육학 군사학 문헌정보학 법학 사회학 신문방송학 심리과학 정치외교학 지리학 행정학 경제학 무역학 인류학 기타 사회과학
자연과학
자연과학 일반 물리학 생물학 생활과학 수학·통계학 천문학 지구과학 화학 기타 자연과학
공학
공학 일반 건축공학 기계공학 산업공학 재료·에너지공학 전기전자공학 조선해양공학 화학공학 컴퓨터학 기타공학
의약학
의학 일반 간호학 수의학 약학 한의학 기초의학 임상의학 기타 의약학
농수해양학
농수해양학 일반 농학 수산학 식품과학 임학 축산학 해상운송학 기타 농수해양학
예술체육학
예술 일반 디자인 미술 미용 사진 음악학 의상 체육 공연매체예술 기타 예술체육학
복합학
학제간연구 과학기술학 뇌인지과학 기술정책 기타 복합학

ENG

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한고혈압학회 Clinical Hypertension Clinical Hypertension 제18권 제3호
발행연도
2012.1
수록면
88 - 96 (9page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background: Valsartan is an angiotensin II receptor blocker and is used for patient with hypertension. Although response to valsartan varies each individual, there is no study about factors affecting the variability of valsartan response. Methods: To investigate the effects of valsartan on the baseline characteristics of blood pressure, single group, open label, pre- and postcomparison clinical study was conducted. Total 21 male Korean volunteers were enrolled. Each subject was administered no drugs in first period and valsartan 80 mg (Diovan HCT) in second period. For pharmacodynamic analysis, 24 hours blood pressure changes were monitored by ambulatory blood pressure monitoring. Twenty-four hour blood pressure changes were matched to valsartan concentration and analyzed by correlation analysis. Changes in blood pressure pattern were also analyzed. Subjects were divided into responder, non-responder, and reverse responder according to pre- and post- 24 hours blood monitoring results. For determination of pharmacokinetic parameters, plasma concentration of valsartan was measured by a validated ultra-performance liquid chromatography-tandem mass spectrometry method. Pharmacokinetic parameters including area under the plasma concentration versus time curve from 0 hour to the last measurable concentration (AUCt), area under the plasma concentration versus time curve extrapolated to infinity, maximum plasma concentration (Cmax), and time required to reach maximum plasma concentration (Tmax) were calculated by noncompartmental models in the BA-CALC 2008 program ver. 1.0.0. Results: There were no significant associations between blood pressure changes and pharmacokinetic parameters of valsartan. Blood pressure pattern change analysis showed significant results. For AUCt, total amount of absorbed valsartan was 25,808 ± 6,863.0 ng․hr/mL , 20,683 ± 8,782.7ng․hr/mL, and 12,502 ± 5,566.6 ng․hr/mL in responder, non-responder, and reverse responder, respectively (p = 0.041). In Cmax, maximum concentration of valsartan was 4,314 ± 1,522.6 ng/mL, 2,588 ± 1,273.9 ng/mL, and 2,056 ± 1,075.5 ng/mL,respectively. Conclusions: These results showed that response to valsartan was not associated with blood concentration in healthy volunteers and changes in blood pressure patterns to valsartan might be associated with the amount of drugs which are absorbed to subjects.
#Valsartan #Pharmacokinetics #Pharmacology #Blood pressure monitoring

목차

등록된 정보가 없습니다.

참고문헌 (13)

참고문헌 신청
Asmar R / 2010 / Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy : impact of age and gender / Clin Exp Hypertens 32 : 4 google schola Cohn JN / 1999 / Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial / Cardiology 91 (1) : 19 ~ 22 google schola Corea L / 1996 / Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension : a comparative study of the efficacy and safety against amlodipine / google schola Criscione L / 1993 / Pharmacological profile of valsartan : a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype / Br J Pharmacol 110 : 7 google schola Konoshita T / 2009 / Genetic variant of the Renin-Angiotensin system and diabetes influences blood pressure response to Angiotensin receptor blockers / Diabetes Care 32 : 14 google schola

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0